Download Files:
Products Details
Product Description
– αGalCer-RBD is a self-adjuvanting lipoprotein conjugate. αGalCer-RBD induces potent immunity against SARS-CoV-2 and its variants of concern. αGalCer-RBD conjugate induces RBD-specific, cytokine-producing T cell development. αGalCer-RBD has great potential to be an effective COVID-19 vaccine candidate. α-Galactosylceramide (αGalCer) is a potent invariant natural killer T cell (iNKT) agonist[1]. RBD: receptor-binding domain
Web ID
– HY-144120
Shipping
– Room temperature
Applications
– COVID-19-anti-virus
Molecular Formula
– C60H118N4O14
References
– [1]Wang J, et al. Self-Adjuvanting Lipoprotein Conjugate αGalCer-RBD Induces Potent Immunity against SARS-CoV-2 and its Variants of Concern. J Med Chem. 2022;65(3):2558-2570.
Molecular Weight
– 1119.60
SMILES
– O[C@H]1[C@H]([C@H](O[C@@H]([C@@H]1O)OC[C@@H]([C@@H]([C@@H](CCCCCCCCCCCCCC)O)O)NC(C#CC#CC#CC#CC#CC#CC#CC#CC#CC#CC#CC#CC)=O)CNC(COCCOCCOCCNC(CON)=O)=O)O.[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH].[HH]
Clinical Information
– No Development Reported
Research Area
– Infection
Solubility
– 10 mM in DMSO
Target
– SARS-CoV
Pathway
– Anti-infection
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
